243 related articles for article (PubMed ID: 27373856)
21. Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortex.
Egashira N; Iwasaki K; Ishibashi A; Hayakawa K; Okuno R; Abe M; Uchida N; Mishima K; Takasaki K; Nishimura R; Oishi R; Fujiwara M
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1516-20. PubMed ID: 18558456
[TBL] [Abstract][Full Text] [Related]
22. Yokukansan inhibits morphine tolerance and physical dependence in mice: the role of α₂A-adrenoceptor.
Nakagawa T; Nagayasu K; Nishitani N; Shirakawa H; Sekiguchi K; Ikarashi Y; Kase Y; Kaneko S
Neuroscience; 2012 Dec; 227():336-49. PubMed ID: 23069764
[TBL] [Abstract][Full Text] [Related]
23. Effects of geissoschizine methyl ether, an indole alkaloid in Uncaria hook, a constituent of yokukansan, on human recombinant serotonin 7 receptor.
Ueki T; Nishi A; Imamura S; Kanno H; Mizoguchi K; Sekiguchi K; Ikarashi Y; Kase Y
Cell Mol Neurobiol; 2013 Jan; 33(1):129-35. PubMed ID: 22968712
[TBL] [Abstract][Full Text] [Related]
24. Involvement of the benzodiazepine system in the anxiolytic-like effect of Yokukansan (Yi-gan san).
Kamei J; Miyata S; Ohsawa M
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1431-7. PubMed ID: 19647028
[TBL] [Abstract][Full Text] [Related]
25. Yokukansan, a Traditional Japanese Medicine, Enhances the L-DOPA-Induced Rotational Response in 6-Hydroxydopamine-Lesioned Rats: Possible Inhibition of COMT.
Ishida Y; Ebihara K; Tabuchi M; Imamura S; Sekiguchi K; Mizoguchi K; Kase Y; Koganemaru G; Abe H; Ikarashi Y
Biol Pharm Bull; 2016; 39(1):104-13. PubMed ID: 26725433
[TBL] [Abstract][Full Text] [Related]
26. Anxiolytic effect of a herbal medicine, yokukansan, in aged rats: involvement of serotonergic and dopaminergic transmissions in the prefrontal cortex.
Mizoguchi K; Tanaka Y; Tabira T
J Ethnopharmacol; 2010 Jan; 127(1):70-6. PubMed ID: 19799980
[TBL] [Abstract][Full Text] [Related]
27. Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of yokukansan, a traditional Japanese medicine.
Iwasaki K; Kosaka K; Mori H; Okitsu R; Furukawa K; Manabe Y; Yoshita M; Kanamori A; Ito N; Wada K; Kitayama M; Horiguchi J; Yamaguchi S; Takayama S; Fukuhara R; Ouma S; Nakano S; Hashimoto M; Kinoshita T
Psychogeriatrics; 2012 Dec; 12(4):235-41. PubMed ID: 23279145
[TBL] [Abstract][Full Text] [Related]
28. Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder.
Wake R; Miyaoka T; Furuya M; Hashioka S; Horiguchi J
CNS Neurol Disord Drug Targets; 2016; 15(5):551-63. PubMed ID: 27071791
[TBL] [Abstract][Full Text] [Related]
29. Brain distribution of geissoschizine methyl ether in rats using mass spectrometry imaging analysis.
Matsumoto T; Ikarashi Y; Takiyama M; Watanabe J; Setou M
Sci Rep; 2020 Apr; 10(1):7293. PubMed ID: 32350314
[TBL] [Abstract][Full Text] [Related]
30. Protective effects of glycycoumarin and procyanidin B1, active components of traditional Japanese medicine yokukansan, on amyloid β oligomer-induced neuronal death.
Kanno H; Kawakami Z; Tabuchi M; Mizoguchi K; Ikarashi Y; Kase Y
J Ethnopharmacol; 2015 Jan; 159():122-8. PubMed ID: 25446602
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous quantitative analyses of indole and oxindole alkaloids of Uncaria Hook in rat plasma and brain after oral administration of the traditional Japanese medicine Yokukansan using high-performance liquid chromatography with tandem mass spectrometry.
Kushida H; Fukutake M; Tabuchi M; Katsuhara T; Nishimura H; Ikarashi Y; Kanitani M; Kase Y
Biomed Chromatogr; 2013 Dec; 27(12):1647-56. PubMed ID: 23813572
[TBL] [Abstract][Full Text] [Related]
32. Isoliquiritigenin is a novel NMDA receptor antagonist in kampo medicine yokukansan.
Kawakami Z; Ikarashi Y; Kase Y
Cell Mol Neurobiol; 2011 Nov; 31(8):1203-12. PubMed ID: 21691759
[TBL] [Abstract][Full Text] [Related]
33. Ameliorative effect of traditional Japanese medicine yokukansan on age-related impairments of working memory and reversal learning in rats.
Mizoguchi K; Shoji H; Tanaka Y; Tabira T
Neuroscience; 2011 Mar; 177():127-37. PubMed ID: 21195139
[TBL] [Abstract][Full Text] [Related]
34. Yokukansan, a kampo medicine, protects PC12 cells from glutamate-induced death by augmenting gene expression of cystine/glutamate antiporter system Xc-.
Kanno H; Kawakami Z; Mizoguchi K; Ikarashi Y; Kase Y
PLoS One; 2014; 9(12):e116275. PubMed ID: 25551766
[TBL] [Abstract][Full Text] [Related]
35. Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease.
Furukawa K; Tomita N; Uematsu D; Okahara K; Shimada H; Ikeda M; Matsui T; Kozaki K; Fujii M; Ogawa T; Umegaki H; Urakami K; Nomura H; Kobayashi N; Nakanishi A; Washimi Y; Yonezawa H; Takahashi S; Kubota M; Wakutani Y; Ito D; Sasaki T; Matsubara E; Une K; Ishiki A; Yahagi Y; Shoji M; Sato H; Terayama Y; Kuzuya M; Araki N; Kodama M; Yamaguchi T; Arai H
Geriatr Gerontol Int; 2017 Feb; 17(2):211-218. PubMed ID: 26711658
[TBL] [Abstract][Full Text] [Related]
36. Traditional uses, chemical compounds, pharmacological activities and clinical studies on the traditional Chinese prescription Yi-Gan San.
Yang SY; Lin ZX; Xian YF; Zhang HM; Xu HX
J Ethnopharmacol; 2023 Feb; 302(Pt A):115859. PubMed ID: 36280017
[TBL] [Abstract][Full Text] [Related]
37. Daily administration of yokukansan and keishito prevents social isolation-induced behavioral abnormalities and down-regulation of phosphorylation of neuroplasticity-related signaling molecules in mice.
Fujiwara H; Han Y; Ebihara K; Awale S; Araki R; Yabe T; Matsumoto K
BMC Complement Altern Med; 2017 Apr; 17(1):195. PubMed ID: 28376888
[TBL] [Abstract][Full Text] [Related]
38. Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease.
Okahara K; Ishida Y; Hayashi Y; Inoue T; Tsuruta K; Takeuchi K; Yoshimuta H; Kiue K; Ninomiya Y; Kawano J; Yoshida K; Noda S; Tomita S; Fujimoto M; Hosomi J; Mitsuyama Y
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):532-6. PubMed ID: 20170698
[TBL] [Abstract][Full Text] [Related]
39. Yokukansankachimpihange, a traditional Japanese (Kampo) medicine, enhances the adaptation to circadian rhythm disruption by increasing endogenous melatonin levels.
Imamura S; Tabuchi M; Oizumi H; Ueki T; Omiya Y; Ikarashi Y; Mizoguchi K
J Pharmacol Sci; 2020 Nov; 144(3):129-138. PubMed ID: 32921394
[TBL] [Abstract][Full Text] [Related]
40. Effects of yokukansan, a traditional Japanese medicine, on memory disturbance and behavioral and psychological symptoms of dementia in thiamine-deficient rats.
Ikarashi Y; Iizuka S; Imamura S; Yamaguchi T; Sekiguchi K; Kanno H; Kawakami Z; Yuzurihara M; Kase Y; Takeda S
Biol Pharm Bull; 2009 Oct; 32(10):1701-9. PubMed ID: 19801831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
